The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2026
Filed:
Mar. 14, 2023
Methods of reducing the likelihood of carcinoid heart disease in patients with neuroendocrine tumors
Applicant:
Tersera Therapeutics Llc, Deerfield, IL (US);
Inventors:
Lonnie Brent, Deerfield, IL (US);
Janine North, Eugene, OR (US);
Assignee:
TerSera Therapeutics LLC, Deerfield, IL (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61B 5/00 (2006.01); A61K 38/31 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61B 5/4848 (2013.01); A61K 38/31 (2013.01); A61P 35/00 (2018.01);
Abstract
Described herein are methods of treating a human patient with a newly diagnosed neuroendocrine tumor, methods of treating patients with neuroendocrine tumors with early signs of carcinoid heart disease who have not had a heart valve replacement, and methods of treating a human patient with the neuroendocrine tumor who has had a recent heart valve replacement. Administering telotristat ethyl to these patients can reduce the development of carcinoid heart disease and improve clinical outcomes.